News >

CLL Research Explores Feasibility of Time-Limited Treatment

Brandon Scalea
Published: Friday, Feb 22, 2019

Nicole Lamanna, MD

Nicole Lamanna, MD

Although many advances have been made in improving the safety and efficacy of agents available for patients with chronic lymphocytic leukemia (CLL), researchers have put a renewed focus on how to limit the duration of the current therapies, said Nicole Lamanna, MD.

Lamanna highlighted the latest MURANO data in CLL, delving into the need for more studies to test the feasibility of time-limited treatment in this patient population.

OncLive: Please provide some background to the MURANO trial. 

Lamanna: MURANO was a study that enrolled patients with relapsed/refractory CLL and looked at the use of venetoclax and rituximab versus BR. This was a follow-up to a phase I study, which evaluated the combination of venetoclax and rituximab in these patients, and assessed its safety and tolerability. Once that was assessed, of course, investigators went on to compare it with a chemoimmunotherapy arm, namely BR, because this a frequently used combination in the United States. These data were initially presented in 2017, and this year we presented the 3-year follow-up. This trial looked at having venetoclax stopped; it is one of the first trials looking at a fixed-duration therapy with venetoclax.

In other words, [patients] can stop these oral therapies, have a long response, and their time to next treatment will be much longer. This is what we used to do with chemoimmunotherapy—we would give 6 cycles of BR and [the patient] would be done, regardless of response.

What were the updated data presented at the 2018 ASH Annual Meeting?

This was a 3-year follow-up, and the results were very significant. We showed that the PFS with venetoclax and rituximab continued to hold very well at approximately 71% versus BR, which was about 17%. The other follow-up was looking at the patients who stopped venetoclax at 2 years. We were looking at MRD with venetoclax therapy, breaking down the data into undetectable MRD, low MRD, and high MRD. There was a very significant correlation between the patients with undetectable MRD and being in long-term remission.


... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x